You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. MTI-301 a SCD1 inhibitor for the treatment of NASH

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 300

    Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in children and adults associated with diet-associated hepatic lipid accumulation (steatosis), and is a common hepatic manifestation of obesity and metabolic syndromes including diabetes. Modulation Therapeutics is developing a stearoyl- coenzyme A desaturase-1 (SCD1) inhibitor for the treatment of NAFLD a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates

    SBC: Cellia Science, Inc.            Topic: NIBIB

    Project Summary/Abstract Bone marrow aspirates are critical to the diagnosis, staging, and monitoring of hematologic conditions and cancers (e.g., leukemia, aplastic anemia, sickle cell disease, and metastasis of solid tumors), but 8-50% of aspirations are unsuccessful due to operator technique, hemodilution, or underlying pathology. Because this process is manual and error-prone, there is an oppo ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a Digital Training and Assessment Platform to Disseminate a Successful NIH-Supported College Preparation Model for Diversifying the U.S. Biomedical Workforce

    SBC: MOTHER COMMUNICATIONS CO.            Topic: 500

    Abstract: Developing a Digital Training and Assessment Platform to Disseminate a Successful NIH- Supported College Preparation Model for Diversifying the U.S. Biomedical Workforce This Phase 1 SBIR project will design and test a digital training and assessment platform—HSTA Hatch—to help geographic regions outside West Virginia (WV) establish workforce development programs for grade 9-12 youth ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Portable Scaled Sample Preparation Device for Concentration and Recovery of Bacterial Contaminants

    SBC: VIC FOUNDRY INC            Topic: NIAID

    Project SummaryThe overall goal of this SBIR project is to establish the technical feasibility for commercialization of a patent-pending sample preparation technology that concentrates and recovers microbial contaminants from appropriately scaled water samples. The proposed product is affordable, versatile, reusable, portable, and automated device with no moving parts, suitable for on-site or in-f ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Microfluidic Cartridge for Point-of-Care Hematology Analysis

    SBC: Cellia Science, Inc.            Topic: NHLBI

    Project Summary/Abstract Evaluation for neutropenia and/or thrombocytopenia requires a 5-part white blood cell (WBC) differential with platelet count. Currently, instruments capable of these measurements must be operated in a CLIA-certified laboratory and rely on complex workflows involving multiple reagents, extensive calibration and maintenance, and operation by highly trained personnel. Turnaro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)

    SBC: BIOSTRATAGIES LC            Topic: 105

    PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Advanced Development of Gemini-DHAP

    SBC: SFC FLUIDICS, INC.            Topic: 200

    Advanced Development of GeminiTM-DHAP Project Summary:The Specific Aim of this Direct to Phase II project is to develop a discrete, low-profile, dual hormone artificial pancreas device, the GeminiTM-DHAP, using SFC Fluidics' enabling microfluidic technologies to deliver both insulin and glucagon as recommended by a dual-hormone algorithm in response to continuous glucose monitor readings. The Gemi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases

    SBC: BIOSTRATAGIES LC            Topic: NICHD

    Mucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal, and central nervous systems leading to devastating quality-of-life and early death. The disease is due to deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progre ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases

    SBC: Nephropathology Associates, PLC            Topic: 400

    Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Modulation of cancer induced immune suppression via inhibition of SCD1

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    PROJECT SUMMARY Metabolic reprogramming plays a critical role in carcinogenesis, in part due its ability to promote immunesuppressive properties within tumors. It remains unclear whether inhibition of fatty acid metabolism in tumorsaffects their immunogenicity. We show that inhibition of stearoyl CoA desaturase 1 (SCD1), the rate limitingenzyme involved in fatty-acid synthesis converting saturated ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government